Alzheimer’s drug that slows cognitive decline gets FDA approval

Holly Fernandez Lynch of the Perelman School of Medicine and the Leonard Davis Institute says that the debate over Alzheimer’s drug lecanemab underscores the complicated risk-benefit calculation for patients.

・ From The Washington Post